New FDA Fecal Transplant Guidance Should Ease Ferring’s Path To Commercialization

Final guidance excludes stool banks, putting in place more limited enforcement discretion regarding the requirement of an investigational new drug application for use of fecal transplants to treat C. diff infections, likely paving way for shift to any FDA-approved product.

open path with sunrise
FDA finalized a draft guidance on unapporved fecal transplants for C. diff infections ahead of likely first product approval. • Source: Shutterstock

Ferring Pharmaceuticals has one less barrier to uptake of its standardized fecal microbiota transplant treatment for recurrent Clostridioides difficile following US Food and Drug Administration finalization of a 2016 guidance that narrows the circumstances under which the agency will exercise enforcement discretion and permit the use of unapproved products.

Ferring’s Rebyota, received a favorable FDA advisory committee review in September, in large part due to the preference of agency...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Compliance

More from Pink Sheet